Pharmacometric approaches to guide dose selection of the novel GPR40 agonist TAK-875 in subjects with type 2 diabetes mellitus

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 1, 2013, Pages

  Naik, H ^a   Lu, J ^b   Cao, C ^a   Pfister, M ^b   Vakilynejad, M ^a   Leifke, E ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Quantitative Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; TAK 875; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIMULATION; TREATMENT DURATION;

EID: 84881120148     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2012.23     Document Type: Article

References (37)

1. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004). (Pubitemid 38579764)
2. National Diabetes Statistics, 2007. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Publication No. 08-3892. 2008.
3. American Diabetic Association. National Diabetes Fact Sheet, 2011. .(2011). Accessed 1 March 2012.
4. Saydah, S.H., Fradkin, J. & Cowie, C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291, 335-342 (2004). (Pubitemid 38101606)
5. Negoro N. et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. 1, 290-294 (2010).
6. Tsujihata, Y. et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J. Pharmacol. Exp. Ther. 339, 228-237 (2011).
7. Naik, H. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebocontrolled single oral dose rising study in healthy volunteers. J. Clin. Pharmacol. 52, 1007-1016 (2012).
8. Matsuno K., Hirayama M., Araki T., Dote N., Kondo T. & Nakamura K. Pharmacokinetics, safety and tolerability of single and multiple doses of TAK-875, a novel GPR40 agonist, in Japanese healthy male subjects. Diabetes 59, A193 (2010).
9. Leifke, E. et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin. Pharmacol. Ther. 92, 29-39 (2012).
10. Burant, C.F. et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379, 1403-1411 (2012).
11. Tanaka, E. Gender-related differences in pharmacokinetics and their clinical significance. J. Clin. Pharm. Ther. 24, 339-346 (1999). (Pubitemid 29520783)
12. Greenblatt, D.J. & von Moltke, L.L. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J. Clin. Pharmacol. 48, 1350-1355 (2008).
13. Ribbing, J., Hamrén, B., Svensson, M.K. & Karlsson, M.O. A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J. Clin. Pharmacol. 50, 861-872 (2010).
14. de Winter, W. et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J. Pharmacokinet. Pharmacodyn. 33, 313-343 (2006).
15. Rohatagi, S. et al. Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J. Clin. Pharmacol. 48, 1420-1429 (2008).
16. Marino, M.T. et al. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin. Pharmacol. Ther. 88, 243-250 (2010).
17. Frey, N., Laveille, C., Paraire, M., Francillard, M., Holford, N.H. & Jochemsen, R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br. J. Clin. Pharmacol. 55, 147-157 (2003). (Pubitemid 36240273)
18. Verma, M., Paneri, S., Badi, P. & Raman, P.G. Effect of increasing duration of diabetes mellitus type 2 on glycated hemoglobin and insulin sensitivity. Indian J. Clin. Biochem. 21, 142-146 (2006).
19. Rodbard, H.W. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract. 13SUPPL. 1, 1-68 (2007).
20. Nathan, D.M. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203 (2009).
21. Schade, D.S., Jovanovic, L. & Schneider, J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J. Clin. Pharmacol. 38, 636-641 (1998). (Pubitemid 28354902)
22. Simonson, D.C., Kourides, I.A., Feinglos, M., Shamoon, H. & Fischette, C.T. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 20, 597-606 (1997). (Pubitemid 27143421)
23. Amaryl [package insert]. Bridgewater, NJ; Sanofi-Aventis, 2012.
24. Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D. & Khatami, H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49, 2564-2571 (2006).
25. Rosenstock, J., Aguilar-Salinas, C., Klein, E., Nepal, S., List, J. & Chen, R. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr. Med. Res. Opin. 25, 2401-2411 (2009).
26. Lukashevich, V., Schweizer, A., Shao, Q., Groop, P.H. & Kothny, W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes. Obes. Metab. 13, 947-954 (2011).
27. Onglyza [package insert], Prinston, NJ; Bristol-Myers Squibb Company, 2011.
28. Januvia [package insert], Whitehouse Station, NJ; Merck & Co, 2012.
29. Nonmem. NONMEM Users Guide: Introduction to NONMEM 7. (ICON Development Solutions, Ellicott City, MD, 2010).
30. Landersdorfer, C.B. & Jusko, W.J. Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin. Pharmacokinet. 47, 417-448 (2008). (Pubitemid 351861956)
31. Lin, S. & Chien, Y.W. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models. J. Pharm. Pharmacol. 54, 791-800 (2002). (Pubitemid 34649465)
32. Wählby, U., Jonsson, E.N. & Karlsson, M.O. Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28, 231-252 (2001). (Pubitemid 32643366)
33. Ette, E.I., Williams, P.J., Kim, Y.H., Lane, J.R., Liu, M.J. & Capparelli, E.V. Model appropriateness and population pharmacokinetic modeling. J. Clin. Pharmacol. 43, 610-623 (2003). (Pubitemid 36613120)
34. Mandema, J.W., Gibbs, M., Boyd, R.A., Wada, D.R. & Pfister, M. Model-based metaanalysis for comparative efficacy and safety: application in drug development and beyond. Clin. Pharmacol. Ther. 90, 766-769 (2011).
35. Mandema, J.W., Boyd, R.A. & DiCarlo, L.A. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response metaanalysis. Clin. Pharmacol. Ther. 90, 820-827 (2011).
36. Mandema, J.W., Salinger, D.H., Baumgartner, S.W. & Gibbs, M.A. A dose-response meta- analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin. Pharmacol. Ther. 90, 828-835 (2011).
37. Mandema J., Sweeney K., Terra S. & Sahasrabudhe V. Model-Based Meta-Analysis of the HbA1c Lowering Effect of PF-04971729, a Sodium Glucose Co-Transporter-2 Inhibitor (SGLT2i), in Comparison with Other SGLT2i and Anti-Diabetic Agents (ADA). [Abstract]. Diabetes 61 SUPPL. 1, A1015 (2012).